The study conducted by Western University of Health Sciences aims to evaluate the efficacy and safety of efinaconazole 10% solution in treating onychomycosis specifically in diabetic patients, a demographic significantly affected by this condition. With approximately 26 million Americans suffering from diabetes and one-third experiencing toenail onychomycosis, there exists a substantial market opportunity. The absence of prior studies focusing on efinaconazole in this patient population may provide a competitive edge, positioning efinaconazole as a preferred treatment option. The results could enhance market penetration and inform future marketing strategies, particularly in targeting diabetic patients who are often underserved in this therapeutic area.